BH3 Domain of BAD Is Required for Heterodimerization with BCL-XL and Pro-apoptotic Activity*

BAD interacts with anti-apoptotic molecules BCL-2 and BCL-XL and promotes apoptosis. BAD is phosphorylated on serine residues in response to a survival factor, interleukin-3. Phosphorylated BAD cannot bind to BCL-XL or BCL-2 at membrane sites and is found in the cytosol bound to 14-3-3. We report here that deletion mapping and site-directed mutagenesis identified a BH3 domain within BAD that proved necessary for both its heterodimerization with BCL-XL and its death agonist activity. Substitution of the conserved Leu151 with Ala in the BH3 amphipathic α-helix abrogated both functions. The BAD Leu151 mutant was predominantly in the cytosol bound to 14-3-3. The BH3 domain of BCL-2 also proved important for BCL-2/BAD interaction. These results establish a critical role for a BH3 domain within BAD and provide evidence that BAD may function as a death ligand whose pro-apoptotic activity requires heterodimerization with BCL-XL.

[1]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[2]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[3]  C. Milliman,et al.  BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.

[4]  E. White,et al.  Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K , 1996, Molecular and cellular biology.

[5]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[6]  J. Hunter,et al.  A Peptide Sequence from Bax That Converts Bcl-2 into an Activator of Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[7]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[8]  E. Cheng,et al.  Bax-independent inhibition of apoptosis by Bcl-XL , 1996, Nature.

[9]  S. Farrow,et al.  New members of the Bcl-2 family and their protein partners. , 1996, Current opinion in genetics & development.

[10]  J. M. Boyd,et al.  Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. , 1995, Oncogene.

[11]  T. Chittenden,et al.  A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. , 1995, The EMBO journal.

[12]  Z. Oltvai,et al.  Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[14]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[15]  Z. Oltvai,et al.  BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax , 1994, Nature.

[16]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[17]  W. Rutter,et al.  Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. , 1992, Science.

[18]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.